Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients: a Danish cohort study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Evaluation of 2D super-resolution ultrasound imaging of the rat renal vasculature using ex vivo micro-computed tomography

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Automatic airway segmentation from computed tomography using robust and efficient 3-D convolutional neural networks

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Cardiac hypoxic resistance and decreasing lactate during maximum apnea in elite breath hold divers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Detection and characterization of lung cancer using cell-free DNA fragmentomes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Protein-altering germline mutations implicate novel genes related to lung cancer development

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Deirdre Cronin-Fenton
  • Tapashi Dalvi
  • Naimisha Movva
  • Lars Pedersen
  • Hanh Hansen
  • Jon Fryzek
  • Elizabeth Hedgeman
  • Anders Mellemgaard
  • Torben R. Rasmussen
  • Norah Shire
  • Stephen Hamilton-Dutoit
  • Mette Nørgaard
Vis graf over relationer

Programmed cell death receptor ligand-1 (PD-L1) expression, KRAS (KRASm) and EGFR (EGFRm) mutations may influence non-small cell lung cancer (NSCLC) prognosis. We aimed to evaluate PD-L1 expression, KRASm, and EGFRm and survival among stage III unresected NSCLC patients. Using Danish registries, we collected data on stage III unresected NSCLC patients diagnosed 2001-2012 and paraffin-embedded tumor tissue from pathology archives. We assessed PD-L1 expression in tumors and tumor-infiltrating immune cells (ICs) by immunohistochemistry ([Formula: see text] 1% threshold for PD-L1+). We genotyped KRAS and EGFR. Follow-up extended from 120 days post-diagnosis to death, emigration, or 31/12/2014. We computed median survival using Kaplan-Meier methods, and hazard ratios (HRs) using Cox regression associating the biomarkers with death, adjusting for confounders. Among 305 patients, 48% had adenocarcinoma; 38% squamous cell carcinoma. Forty-nine percent had PD-L1+ tumors-51% stage IIIA and 26% KRASm. Few (2%) patients had EGFRm. Median survival in months was 14.7 (95% CI = 11.8-17.9) and 13.4 (95% CI = 9.5-16.3) in PD-L1+ and PD-L1- tumors, respectively. KRASm was not associated with death (HR = 1.06, 95% CI = 0.74-1.51 versus wildtype). PD-L1+ tumors yielded a HR = 0.83 (95% CI = 0.63-1.10); PD-L1+ ICs a HR = 0.51 (95% CI = 0.39-0.68). Tumor expression of PD-L1 did not influence survival. PD-L1+ ICs may confer survival benefit in stage III unresected NSCLC patients.

OriginalsprogEngelsk
Artikelnummer16892
TidsskriftScientific Reports
Vol/bind11
Udgave nummer1
ISSN2045-2322
DOI
StatusUdgivet - dec. 2021

Bibliografisk note

Funding Information:
This work was funded by AstraZeneca as a research grant to (and administered by) Aarhus University, Denmark.

Publisher Copyright:
© 2021, The Author(s).

ID: 69367084